SI030011: Canagliflozin-d6 label-new 5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosyl)onicacid]-(2→6)-(β-D-galactopyranosyl)-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranoside

5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosyl)onicacid]-(2→6)-(β-D-galactopyranosyl)-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranoside

N-α-Fmoc-N-γ-(2-acetamido-2-deoxy-3

9-trioxaundecyl) 2-acetamido-2-deoxy-α-D-galactopyranoside

This compound presents a terminal Galα1-3 linkage on a LacNAc core

SI030011: Canagliflozin-d6 label-new 5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosyl)onicacid]-(2→6)-(β-D-galactopyranosyl)-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranosideC24H19D6FO5S 450. 55 Diabeties Type 2 Canagliflozin d6 (2S,3R,4R,5S,6R) 2 {3 [5 [4 Fluoro phenyl) thiophen 2 ylmethyl] 4 methyl phenyl} 6 hydroxymethyl tetrahydro pyran 3,4,5 triol d6; (1S) 1,5 Anhydro 1 C [3 [[5 (4 fluorophenyl) 2 thienyl]methyl] 4 methylphenyl] D glucitol d6; Invokana d6